Roivant valued at $7B in blank-check merger, bucking SPAC slowdown

Roivant valued at $7B in blank-check merger, bucking SPAC slowdown

Source: 
BioPharma Dive
News Tags: 
snippet: 

Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at $7.3 billion.